Davita (DVA) was downgraded by Goldman Sachs (GS) to neutral from buy with a price target of $120, as the stock is higher by 67% during the past 14 months and lacks catalysts to drive it much higher in the near term.
Shares are lower by about 1.8 percent.
Alexion Pharmaceuticals (ALXN) had its numbers reduced by Jefferies (JEF) due to a delay in the launch of Soliris. A hold rating was issued with a price target of $88.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.